Axalta Q1 2026 net sales dip to $1.25 billion; diluted EPS $0.42 vs. $0.45
Axalta reported first-quarter 2026 results on April 30, 2026. Net sales were $1.25 billion, down $8 million year over year, and net income fell $8 million to $91 million, with diluted EPS of $0.42 versus $0.45, though adjusted EBITDA of $259 million was slightly above the company's first-quarter guidance. The company also gave full-year 2026 adjusted EBITDA guidance of $1.14 billion to $1.17 billion and said it remains on track for the proposed merger of equals with AkzoNobel.
Key points
- Net sales of $1.25 billion, down $8 million year over year; net income of $91 million versus $99 million in Q1 2025
- Diluted EPS of $0.42 versus $0.45; adjusted diluted EPS of $0.56, down $0.03 year over year
- Adjusted EBITDA of $259 million, down $11 million, with a 20.6% margin; operating cash flow of $68 million, up $42 million
- Full-year 2026 guidance: adjusted EBITDA $1.14 billion to $1.17 billion; adjusted diluted EPS $2.55 to $2.70; Q2 2026 adjusted EBITDA $280 million to $290 million
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 30, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.